Bpgbioincis A Clinical Stage Biopharmaceutical Company Based In The Greater Boston Areathe Company Specializes In Ai Driven Drug Discovery And Developmentfocusing On Mitochondrial Biology And Protein Homeostasis To Meet Medical Needs In Oncologyrare Diseasesand Neurologyfounded By A Team Of Experts From Academia And Pharmaceuticalsbpgbio Leverages Its Proprietary Nai Interrogative Biology Platform To Model Patient Biology Using Advanced Bayesian Ai The Nai Platform Conducts Causal Ai Analysis On Longitudinal Patient Data To Identify Therapeutic Targets And Biomarkersvalidated Through Clinical Trialsbpgbio S Pipeline Includes Late Stage Clinical Candidates Targeting Conditions Such As Primary Coq10 Deficiencyglioblastomapancreatic Cancerepidermolysis Bullosaand Sarcopeniathe Company Has Generated Over 400 Patents And Has Developed A First In Class Platform For Targeted Protein Degradationfocusing On Disease Causing Proteinsbpgbio S Innovative Approach Has Earned Recognitionincluding The Title Of 2024 Biotech Ai Company Of The Year By Biotech Breakthrough Awards
